According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7 trillion in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity. Escalating health care costs are also bound to be of major concern to Astiva Health and other providers of health insurance policies.
The surge in health care expenditure highlights the growing financial burden on the U.S. economy, as spending now accounts for a significant share of GDP. The sustained growth rate, exceeding 7% for three years, outpaces inflation and wage increases, putting pressure on both public programs like Medicare and Medicaid, as well as private insurers. The role of GLP-1 drugs, originally developed for diabetes but increasingly prescribed for weight loss, is particularly notable. These medications, including popular brands like Ozempic and Wegovy, come with high price tags, often exceeding $1,000 per month without insurance.
The implications for health insurers such as Astiva Health are profound. Rising drug costs force insurers to adjust premiums, benefit designs, and formularies to maintain financial stability. This can lead to higher out-of-pocket costs for consumers or more restrictive coverage policies. For employers providing health benefits, the escalating costs may result in reduced benefits or increased employee contributions. The broader economic impact includes potential strain on household budgets and reduced disposable income as more money is directed toward health care.
The CMS data underscores a long-term trend of increasing health care spending in the U.S., which has been a persistent policy challenge. Efforts to contain costs, such as drug price negotiations under the Inflation Reduction Act, are still unfolding and may take years to show measurable effects. Meanwhile, the demand for GLP-1 drugs continues to rise, fueled by high obesity rates and aggressive marketing. As the population ages and chronic conditions become more prevalent, the trajectory of health care spending remains a critical issue for policymakers, insurers, and patients alike.
For more details, the full report is available through CMS. This news was originally reported by BioMedWire, a platform covering developments in the biotechnology and life sciences sectors.
